Oneness Biotech Co., Ltd. (LUX:ONES)

Market Cap	771.51M -30.3%
Revenue (ttm)	3.28M +4.6%
Net Income	-39.22M
EPS	-0.08
Shares Out	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Average Volume	n/a
Open	n/a
Previous Close	9.60
Day's Range	n/a
52-Week Range	7.80 - 12.90
Beta	n/a
RSI	40.00
Earnings Date	Mar 6, 2026

About Oneness Biotech

Oneness Biotech Co., Ltd. engages in the research, development, and sale of new drugs, pharmaceuticals, and health products in Taiwan. It offers Fespixon cream for diabetic foot ulcers, and Bonvadis, an innovative wound care medical device. The company develops ON101, which is in Phase III clinical trials for treating chronic diabetic foot ulcers. It is also developing FB825, which is in Phase IIa clinical trial for treating atopic dermatitis and allergic asthma; FB704A that has completed Phase I clinical trial for the treatment of rheumatoid a...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 2008
• Employees: 43
• Stock Exchange: Luxembourg Stock Exchange
• Ticker Symbol: ONES

Financial Performance

In 2024, Oneness Biotech's revenue was 117.93 million, an increase of 35.89% compared to the previous year's 86.78 million. Losses were -1.17 billion, -11.25% less than in 2023.

Financial numbers in TWD